Phenotypes associated with this allele

• Allele Symbol: Lepr^tm1Rck
• Allele Name: targeted mutation 1, Jeffrey M Friedman
• Allele ID: MGI:2176774
• Summary: 4 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
hm1	Lepr^tm1Rck/Lepr^tm1Rck	involves: 129	MGI:2182821
cn2	Lepr^tm1Rck/Lepr^tm1Rck Ndor1^Tg(UBC-cre/ERT2)1Ejb/Ndor1^+	involves: 129 * C57BL/6	MGI:7782473
cn3	Lepr^tm1Rck/Lepr^tm1.1Rck Tg(Alb1-cre)1Rck/0	involves: 129P2/OlaHsd * C57BL/6 * CBA	MGI:2176781
cn4	Lepr^tm1Rck/Lepr^tm1.1Rck Tg(Syn1-cre)671Jxm/0	involves: 129P2/OlaHsd * C57BL/6 * CBA	MGI:2176782

Genotype
MGI:2182821

hm1

• Allelic Composition: Lepr^tm1Rck/Lepr^tm1Rck
• Genetic Background: involves: 129

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

normal phenotype

no abnormal phenotype detected ( J:72241 )

Genotype
MGI:7782473

cn2

• Allelic Composition: Lepr^tm1Rck/Lepr^tm1Rck; Ndor1^{Tg(UBC-cre/ERT2)1Ejb}/Ndor1⁺
• Genetic Background: involves: 129 * C57BL/6

growth/size/body

obese ( J:344866 )

• mice gain approximately 17-19 grams over 4 weeks after tamoxifen treatment

homeostasis/metabolism

increased circulating leptin level ( J:344866 )

• tamoxifen-treated mice develop hyperleptinemia

• hyperleptinemia in tamoxifen-treated mice is resistant to auranofin treatment

decreased physiological sensitivity to xenobiotic ( J:344866 )

• tamoxifen-treated mice lack metabolic responses to the drug auranofin, with no effect on hyperleptinemia, food intake, respiratory exchange ratio, activity, insulin and glucose tolerance, fasting insulin levels, or fatty liver and auranofin treatment does not increase fasting serum free fatty acids as in wild-type mice

• tamoxifen-treated mice lack the anti-inflammatory responses to auranofin in epididymal white adipose tissue (eWAT) that are seen in wild-type mice and auranofin treatment does not increase eWAT oxygen consumption rates

Genotype
MGI:2176781

cn3

• Allelic Composition: Lepr^tm1Rck/Lepr^tm1.1Rck; Tg(Alb1-cre)1Rck/0
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6 * CBA

normal phenotype

no abnormal phenotype detected ( J:72241 )

• normal body weight, normal amounts of adipose tissue, normal clinical chemistry and normal liver

Genotype
MGI:2176782

cn4

• Allelic Composition: Lepr^tm1Rck/Lepr^tm1.1Rck; Tg(Syn1-cre)671Jxm/0
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6 * CBA

adipose tissue

increased total body fat amount ( J:72241 )

growth/size/body

abnormal body composition ( J:72241 )

• increased adipose tissue mass and decreased lean tissue mass

increased body weight ( J:72241 )

• observed after 5 weeks of age

homeostasis/metabolism

hyperglycemia ( J:72241 )

• 2.3 fold greater plasma glucose levels in females compared to littermates; males normal

increased circulating insulin level ( J:72241 )

• hyperinsulinemia; 6 fold greater plasma insulin levels in males and 16.1 fold greater levels in females compared to littermates

increased circulating leptin level ( J:72241 )

• 5.8 fold greater in males and 8.3 fold greater in females compared to littermates

liver/biliary system

hepatic steatosis ( J:72241 )

• enlarged liver due to fatty deposits